Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Alzeca Biosciences Inc.

Latest From Alzeca Biosciences Inc.

Venture Funding Deals: Gene Editing Attracts Big Investors, Roivant Sets Financing Record

In the largest private biopharma round to date, Roivant raises $1.1bn to fund new subsidiaries. The next highest round in August was for gene-editing-focused Homology Medicines.

StartUps and SMEs Financing
See All

Company Information

  • Industry
  • Biotechnology
    • Liposomes
    • Nanotechnology, Chips, etc.
  • Medical Devices
    • Diagnostic Imaging Equipment & Supplies
      • MRI, NMR
  • Pharmaceuticals
    • Drug Delivery
      • Site Specific
    • Radiopharmaceuticals, Contrast Agents
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Alzeca Biosciences Inc.
  • Senior Management
  • Carlo Medici, CEO
    Thomas Hale, COO
    Brenda Fielding, VP, Reg. Affairs
  • Contact Info
  • Alzeca Biosciences Inc.
    Phone: (713) 850-0083
    1800 Bering Dr.
    Ste. 430
    Houston, TX 77057